Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen to Provide Technologies for Blood Screening Program in Brazil

NEW YORK (GenomeWeb News) – Qiagen today said that it will provide molecular sample and assay technologies for a PCR-based blood screening program for HIV and hepatitis C virus in Brazil.

The contract — signed with Bio-Manguinhos, which provides vaccines and diagnostics to the Brazilian Ministry of Health — will run for five years, following approval by Brazilian patent authorities. The deal contains options for subsequent extensions, said Qiagen.

The new, national screening is scheduled to start next year. Qiagen estimated that around 5 million blood donations are performed each year in Brazil.

"The new program marks the effort to complement these traditional, immunodiagnostic tests with nucleic-acid-based, molecular assays that are considered significantly more sensitive in detecting infection," Qiagen said in a statement.

The firm recently has been expanding its presence in the Latin and South American markets. Late last year, Qiagen announced that the Mexican Public Health Agency would launch a human papillomavirus screening program that would include the use of its Digene molecular HPV assay.

Filed under

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.